Advantages of using a portable cardiac monitor in outpatients with paroxysmal atrial fibrillation

Aim. To study the advantages of using a portable electrocardiographic (ECG) monitor in outpatients with paroxysmal atrial fibrillation (AF).

Material and methods. We examined 88 patients (26 men, 62 women, mean age, 63 [57;68] years) with paroxysmal AF with an average frequency of arrhythmia episodes of 1,0 [0.3;3.75] per month. Forty three (49%) patients were included in the remote monitoring (RM) group using the ECG Dongle monitor, and 45 (51%) patients were included in the conventional monitoring (CM) group. Patients underwent scheduled examinations 2, 6 and 12 months after the start of therapy. Unscheduled consultations were carried out in case of AF recurrence. Patients from the RM group, using portable cardiac monitor, additionally self-registered ECG 1 time per week and in case of symptoms suggestive of AF. ECG strips were sent to the clinical investigator for analysis.

Results. With the help of portable cardiac monitor, 2477 ECG strips were collected and analyzed: 2159 (87,2%) — sinus rhythm, 318 (12,8%) — AF and atypical atrial flutter. Forty four episodes of AF in 3 patients were asymptomatic. In addition, 211 (8,5%) sinus rhythm ECG strips were recorded by 13 patients with symptoms suggestive of AF. In the RM group, 7 (16%) patients were hospitalized due to recurrent AF, while in the CM group, 20 (44%) patients (p=0,004). The total number of emergency hospitalizations was 8 and 29 in the RM and CM groups, respectively. The number of patients who called an ambulance was significantly lower in the RM group: in the CM group, 37 calls for an ambulance were made by 22 patients, while in the RM group — 12 patients made 15 calls (p=0,044). The proportion of calls followed by hospitalization (40 vs 70%, p=0,043) was significantly lower in the RM group.

Conclusion. Remote ECG monitoring using the ECG Dongle system is a useful way to monitor patients with paroxysmal AF, which make it possible to register asymptomatic AF episodes, differentiate the causes of palpitations, and significantly reduce the frequency of emergency calls and hospitalizations.

1. Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449-53.

2. Kolbin AS, Mosikyan AA, Tatarsky BA. Socioeconomic burden of atrial fibrillation in Russia (2010-2017). J Arrhythmology. 2018;(92):42-8. (In Russ.)

3. Plavunov NF, Gaponova NI, Kadyshev VA, et al. Clinical and statistical evaluation of the calls of patients with atrial fibrillation. The Russian Archives of Internal Medicine. 2018;8(5):389-93. (In Russ.) doi:10.20514/2226-6704-2018-8-5-389-393.

4. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/1560-4071-2021-4594.

5. Petrosyan YM, Dumbadze RD, Bakshanskaya EO, et al. The effectiveness of atrial fibrillation screening with the MyDyagnostick 1001R device in a population and in a group at risk. Russian Family Doctor. 2019;23(4):41-8. (In Russ.) doi:10.17816/RFD18929.

6. Anczykowski J, Willems S, Hoffmann BA, et al. Early detection of symptomatic paroxysmal cardiac arrhythmias by transtelephonic ECG monitoring: impact on diagnosis and treatment of atrial fibrillation. J Cardiovasc Electrophysiol. 2016;27:1032-7.

7. Packer DL, Mark DB, Robb RA, et al; CABANA Investigators. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. Am Heart J. 2018;199:192-9. doi:10.1016/j.ahj.2018.02.015.

8. Yamashita T, Ogawa S, Sato T, et al; J-BAF Investigators. Doseresponse effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study). Circ J. 2009;73(6):1020-7. doi:10.1253/circj.cj-08-1061.

9. Klingenheben T, Albakri A, M Helms T. Transtelephonic ECG Monitoring to Guide Outpatient Antiarrhythmic Drug Therapy in Patients With Non-Permanent Atrial Fibrillation: Efficacy and Safety From a Single-Center Experience. J Atr Fibrillation. 2019;11(6):2161. doi:10.4022/jafib.2161.

10. Chireykin LV, Dovgalevskiy PYa. Remote diagnostic cardiology centers. S-Pb., 1995. 232p. (In Russ.)

11. Bertazzoni G, Genuini I, Aguglia F. Telecar: an Italian telecardiology project. J Telemed Telecare. 1996;2(3):132-5. doi:10.1258/1357633961929943.

12. Devyashina KS, Oganyan KG, Panchoyan SM, et al. The possibility of early diagnostics of atrial fibrillation in patients with high risk of it’s development. Russian Family Doctor. 2018;22(2):14-8. (In Russ.) doi:10.17816/RFD2018214-18.

13. Varma N, Cygankiewicz I, Turakhia M, et al. 2021 ISHNE/ HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. Ann Noninvasive Electrocardiol. 2021;26(2):e12795. doi:10.1111/anec.12795.

14. Kaasenbrood F, Hollander M, de Bruijn SH, et al. Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial. Br J Gen Pract. 2020;70(695):e427-33. doi:10.3399/bjgp20X708161.

15. Atarashi H, Ogawa S, Inoue H; Flecainide Atrial Fibrillation Investigators. Relationship between subjective symptoms and trans-telephonic ECG findings in patients with symptomatic paroxysmal atrial fibrillation and flutter. J Cardiol. 2008;52(2):10210. doi:10.1016/j.jjcc.2008.06.006.

16. Tarakji KG, Wazni OM, Callahan T, et al. Using a novel wireless system for monitoring patients after the atrial fibrillation ablation procedure: the iTransmit study. Heart Rhythm. 2015;12(3):554-9. doi:10.1016/j.hrthm.2014.11.015.

17. Senga M, Fujii E, Sugiura S, et al. The Utility of Transtelephonic Electrocardiograms for Detecting Arrhythmia Recurrences after Radiofrequency Catheter Ablation for Atrial Fibrillation. J Arrhythmia. 2009;25(3):130-4.

18. Gupta D, Vijgen J, Potter T, et al. Quality of life and healthcare utilisation improvements after atrial fibrillation ablation. Heart. 2021;107(16):1296-302. doi:10.1136/heartjnl-2020-318676.

19. Aljuaid M, Marashly Q, AlDanaf J, et al. Smartphone ECG Monitoring System Helps Lower Emergency Room and Clinic Visits in Post-Atrial Fibrillation Ablation Patients. Clin Med Insights Cardiol. 2020;14:1179546820901508. doi:10.1177/1179546820901508.

20. Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004;43:47-52. doi:10.1016/j.jacc.2003.08.027.

21. Vollmer WM, Owen-Smith AA, Tom JO, et al. Improving adherence to cardiovascular disease medications with information technology. Am J Manag Care. 2014;20(SP17):SP502-10.

22. Hickey KT Biviano AB, Garan H, et al. Evaluating the utility of mHealth ECG heart monitoring for the detection and management of atrial fibrillation in clinical practice. J Atr Fibrillation. 2017;9(5):1546. doi:10.4022/jafib.1546.